Companies /Healthcare

Krystal Biotech Inc

NASDAQ: KRYS Biotechnology
$297.21
▼ $0.70 (−0.23%) today
Markets open · 3:55pm ET

24/7 Wall St. View

KRYS at a Glance

Valuation
Market cap
$9.0B
P/E ratio
41.5
Profitability
Revenue (TTM)
$470.0M
Profit margin
47.9%
EPS (TTM)
$7.36
Price
52-week range
$203 – $383
24/7 target
$389.85
Street target
$388.22
Earnings
Next report
Feb 16, 2027
Q3 2026 EPS
$2.05
vs. $1.92 est.
+6.9%

Headquartered in Pittsburgh, PA Fiscal year ends December NASDAQ: KRYS krystalbio.com

About Krystal Biotech

Krystal Biotech, Inc. is a fully integrated, commercial-stage biotechnology company that discovers, develops and commercializes genetic medicines for diseases with high unmet medical need, using an HSV-1-based, redosable gene delivery platform.

Its sole commercial product is VYJUVEK (beremagene geperpavec-svdt). It is a topical, non-invasive gene therapy that delivers two copies of the COL7A1 gene to wounds in patients with dystrophic epidermolysis bullosa (DEB). VYJUVEK is approved in the United States, Europe and Japan. It is sold in the U.S. and in initial international launch markets of Germany, France and Japan, with an Italian launch expected in early 2027 and further European, UK, Australian and Swiss market access efforts underway.

The clinical pipeline spans several therapeutic areas:
- **Dermatology:** KB111 for Hailey-Hailey disease and KB113 for basal cell carcinoma in Gorlin syndrome.
- **Ophthalmology:** KB803 for corneal abrasions in DEB and KB801 for neurotrophic keratitis.
- **Respiratory:** KB407 for cystic fibrosis and KB408 for alpha-1 antitrypsin deficiency lung disease.
- **Oncology:** Inhaled KB707 for non-small cell lung cancer.
- **Aesthetics:** KB304 for décolleté wrinkles, developed through its wholly owned subsidiary Jeune Aesthetics.

The company is profitable and holds about $1.2 billion in cash and investments. It has authorized a share repurchase program of up to $400 million. Updated

KRYS Coverage

Frequently Asked Questions

What does Krystal Biotech do?

Krystal Biotech, Inc. is a fully integrated, commercial-stage biotechnology company that discovers, develops and commercializes genetic medicines for diseases with high unmet medical need, using an HSV-1-based, redosable gene delivery platform. Its sole commercial product is VYJUVEK (beremagene geperpavec-svdt).

What is the KRYS stock price target?

24/7 Wall St.'s 12-month price target for KRYS is $389.85, rated Buy. The Wall Street consensus target is $388.22. KRYS price prediction →